1. Scrip
  2. >>Business
  3. >>Deals

Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase

 
• By Jessica Merrill

Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.

muscle
Pfizer plans to put big marketing muscle behind Nurtec • Source: Shutterstock

Pfizer Inc. is poised to enter the migraine market with the full strength of its marketing power, raising the stakes in an already crowded and competitive commercial market. Pfizer announced a deal on 10 May to buy the migraine specialist Biohaven Pharmaceutical Holding Company Ltd. in a transaction valued at $11.6bn, gaining the oral migraine drug Nurtec ODT (rimegepant) and a nasal spray, zavegepant, pending at the US Food and Drug Administration, as well as five preclinical calcitonin gene-related peptide (CGRP) inhibitor assets.

The deal fulfills Pfizer's promise to investors to expand its late-stage and commercial portfolio with near-term growth drivers and puts...

More from Deals

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By Mandy Jackson

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

 
• By Dexter Jie Yan

Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.

More from Business